SCHEMBL3171807

SCHEMBL3171807

CCOC1OC(=O)C[C@@H]1NC(=O)[C@H]1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 1/20 0.60
TSHR P16473 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
KDM4E B2RXH2 1/20 0.57
LMNA P02545 1/20 0.57
CTSK P43235 2/20 0.56
PRCP P42785 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
CTSB P07858 1/20 0.53
CTSS P25774 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
CTRB1 P17538 1/20 0.52
GFER P55789 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ALDH1A1 P00352 2/20 0.51
CASP1 P29466 1/20 0.51
KMT2A Q03164 2/20 0.50
TP53 P04637 1/20 0.50
MEN1 O00255 1/20 0.50
PREP P48147 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8288895 1.00 KLK7 (0.60) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL3171795 1.00 KLK7 (0.60) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL3179605 1.00 KLK7 (0.60) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL3179613 1.00 KLK7 (0.60) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL13397371 1.00 KLK7 (0.60) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL8287709 0.93 KLK7 (0.59) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL8287710 0.93 KLK7 (0.59) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL994619 0.93 KLK7 (0.59) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL994617 0.93 KLK7 (0.59) KLK7TSHRL3MBTL1KDM4ELMNA
SCHEMBL995731 0.93 KLK7 (0.59) KLK7TSHRL3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105914-A1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-29 US disclosed
US-7652153-B2 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid VERTEX PHARMACEUTICALS INCORPORATED 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105914-A1 CASPASE INHIBITORS AND USES THEREOF CASP1, CASP5, CASP3 KLK7 1031/4885TSHR 4831/4885L3MBTL1 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.